Achieve Life Sciences (ACHV) Common Equity (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Common Equity came in at $10.7 million in Q1 2026, up 3.88% YoY from $10.3 million in Q1 2025, and down 50.38% on a QoQ basis from $21.5 million in Q4 2025.
Achieve Life Sciences (ACHV) Common Equity (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Common Equity data on file, last reported at $10.7 million in Q1 2026.
- Quarterly Common Equity rose 3.88% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (up 3.88% YoY) and the FY2025 annual result came in at $21.5 million, up 2.96% from the prior year.
- Common Equity declined to $10.7 million in Q1 2026, from $21.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $49.5 million in Q1 2024 to a low of -$1.4 million in Q4 2023.
- A 5-year average of $18.7 million and a median of $13.2 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity slumped 117.44% — and 2024, when it soared 11063.88%.
- Tracing ACHV's Common Equity over 5 years: stood at $8.3 million in 2022, then tumbled by 117.44% to -$1.4 million in 2023, then surged by 1543.3% to $20.9 million in 2024, then grew by 2.96% to $21.5 million in 2025, then tumbled by 50.38% to $10.7 million in 2026.
- The last three Common Equity figures came in at $10.7 million (Q1 2026), $21.5 million (Q4 2025), and $33.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | -14.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.68 Mn |
| Mar 31, 2026 | 10.68 Mn |
| Dec 31, 2025 | 21.52 Mn |
| Sep 30, 2025 | 33.62 Mn |
| Jun 30, 2025 | 41.67 Mn |
| Mar 31, 2025 | 10.28 Mn |
| Dec 31, 2024 | 20.90 Mn |
| Sep 30, 2024 | 31.38 Mn |
| Jun 30, 2024 | 42.29 Mn |
| Mar 31, 2024 | 49.46 Mn |
| Dec 31, 2023 | -1.45 Mn |
| Sep 30, 2023 | 4.04 Mn |
| Jun 30, 2023 | 9.70 Mn |
| Mar 31, 2023 | 443,000.00 |
| Dec 31, 2022 | 8.30 Mn |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 13.17 Mn |
| Mar 31, 2022 | 21.43 Mn |
| Dec 31, 2021 | 28.04 Mn |
| Sep 30, 2021 | 34.70 Mn |